Incyte Upgraded by Bank of America - Stock on the Verge of Breaking Out of Base!
Reading Time: 1 minute
Incyte specializes in the research and development of therapeutics primarily aimed at treating cancers and inflammatory diseases. The company has several growth drivers in its portfolio, including Jakafi for the treatment of myelofibrosis. With its Q2 figures, the company has raised its forecast for Jakafi product sales in 2025 from 2.95 to 3 billion USD to 3 to 3.05 billion USD, meaning that this medication will account for more than half of total revenues. Another driver is likely to be the approval of the monoclonal anti-PD-1 antibody called...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
